DIETARY · COSMETIC · THERAPEUTIC · RESEARCH
Peptides
A Sober View
The science, the medicines, the markets, and what we actually know.
Get the book — £14.99 Read a sample
The science, the medicines, the markets, and what we actually know.
Get the book — £14.99 Read a sample
Peptides have gone from a biochemist's word to a mainstream consumer category in five years. Ozempic. Wegovy. Mounjaro. BPC-157. TB-500. Copper peptides. Research peptides. The hype is everywhere, the evidence is uneven, and the regulators are catching up.
Most of what's published on peptides is written by enthusiasts who treat the unregulated market as a parallel medical system. This book treats it as what it actually is — an unregulated market: interesting, important, sometimes useful, sometimes dangerous, and worth understanding properly.
This is the book for the reader who wants the honest picture before they make a decision. Not a protocol. Not a sales pitch. Not a doom-piece. A clear-eyed, journalistic look at the peptide field grounded in the published peer-reviewed literature, the current regulatory actions of the MHRA, FDA, EMA and TGA, and the academic research on the UK peptide user community.
Each chapter opens with a summary box. Read straight through, or skip around.
A taste of the voice and the level of detail throughout the book.
By the time the FDA seized lot PAR0362 in April 2025, the counterfeit Ozempic problem had moved from a regulatory nuisance to a documented public-health concern. The Brookings Institution analysis published that month produced what may be the single most consequential statistic in the unregulated peptide market: roughly 60% of Chinese manufacturers producing semaglutide for export are not legally permitted to distribute the API for human use within China itself.
The implication is uncomfortable. The compound being sold to British, American and European buyers — often through telehealth platforms or messaging-app vendors operating from beyond their regulators' reach — is being manufactured under regulatory standards that the Chinese government itself does not consider adequate for human use.
By 31 December 2024, the FDA's Adverse Event Reporting System contained over 900 reports relating to compounded semaglutide and tirzepatide. Seventeen of those reports involved deaths. The MHRA's October 2024 raid on Alluvi Healthcare in the UK was, in this context, not an isolated enforcement action but part of a much larger pattern…
Every factual claim is sourced. The book draws on the published peer-reviewed literature — Turnock & Hearne 2025 on the UK user community, Vasireddi 2025 on BPC-157, Weber 2017 on seized peptide products, and dozens more.
Covers the most recent MHRA enforcement actions, the FDA's April 2026 reclassification of 12 peptides, the TGA's Schedule 4 designation of BPC-157, and the WADA prohibited list as it stands today.
Orforglipron approval, CagriSema FDA submission, retatrutide phase 3, AI-designed peptides, the 2024 AlphaFold Nobel Prize, and what's actually coming next over the next two to three years.
The UK legal framework is the foreground (Human Medicines Regulations 2012, MHRA enforcement, Yellow Card scheme). The US, EU, Australian and global frameworks are covered in detail. Includes practical guidance by jurisdiction.
This is an educational reference. It will not teach you how to use peptides, where to buy them, or how to dose them. It will help you understand the field deeply enough to make better decisions than you would have made otherwise.
No. The book contains no doses, no protocols, no cycle schedules, no sourcing recommendations, and no instructions for use. It is an educational reference designed to help you understand the peptide field — the science, the licensed medicines, the unregulated market, the regulatory landscape, and the evidence. If you came looking for a protocol, this isn't the book for you.
You receive both a PDF (288 pages, A5, designed for reading on tablet or printing) and a single self-contained HTML file (mobile-responsive, easy to reference). Both formats are included with your purchase and download immediately after payment.
Most peptide books on the market are written by enthusiasts who treat the unregulated market as a parallel medical system, often including doses and protocols for compounds that have not been approved for human use. This book takes a different position: it treats the unregulated market as what it actually is — an unregulated market — and helps you understand the evidence and risks without recommending use.
An independent UK-based writer with a journalist's approach to medical topics. The book is positioned and written as an educational reference, not as the work of a clinician. The author is not a doctor, not a pharmacist, and does not prescribe or recommend treatment.
The book reflects the state of the field as of spring 2026. This includes the FDA's April 2026 approval of orforglipron (Foundayo), the December 2025 CagriSema NDA submission, the FDA's April 2026 reclassification of 12 peptides from Category 2, the Australian TGA's recent enforcement actions, and the most current published academic research. The peptide field moves fast — some details will inevitably evolve. The book is written to give you the underlying framework, not just the news.
Yes. There's a 30-day money-back guarantee. If the book isn't what you expected, request a refund within 30 days through Gumroad — no questions asked.
No. Nothing in the book is medical advice. The book is an educational reference. If you have health concerns, you should speak to a qualified healthcare professional. If you suspect you have purchased a counterfeit or unlicensed medicine, you can report it to the MHRA at gov.uk/mhra.
£14.99. That gets you the PDF and HTML versions of the full book — 288 pages, around 70,000 words, 15 chapters, a 75-term glossary, and a further reading list. Lifetime access through Gumroad. No subscription, no upsells, no follow-up purchases.
An educational reference for the peptide field — researched, sourced, and honestly told.